相关实验视频

Updated: May 29, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

伊诺图祖马布 (Ozogamicin) 作为急性淋巴细胞白血病的第一线治疗方法

Elias J Jabbour¹, Philippe Rousselot², Nicola Gokbuget³

¹Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX.

Clinical lymphoma, myeloma & leukemia

|February 5, 2025

概括

患有费城染色体阴性B细胞急性淋巴细胞白血病 (ALL) 的老年人面临着糟糕的结果. 本综述检查了伊诺图祖马布 (inotuzumab ozogamicin) 作为一线治疗方法,以改善治疗结果并减少化疗毒性.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床试验临床试验

背景情况:

患有费城染色体阴性B细胞急性淋巴细胞白血病 (Ph-B细胞ALL) 的老年人长期表现不佳.
在这个人口群体中观察到高的治疗失败率和并发症,儿童启发的疗法受到毒性限制.
针对性疗法,如伊诺图祖马布 (inotuzumab) 和奥佐加米辛 (InO),对B细胞ALL有很大的前景.

研究的目的:

审查伊诺图祖马布 (inotuzumab) 臭胺素 (InO) 的疗效和安全性,作为Ph-B细胞ALL的老年患者的一线治疗.
在这个患者群体中评估优化前线B细胞向剂的策略.
评估InO在减少对常规化疗的依赖和改善治疗耐受性的潜力.

主要方法:

审查最近的临床试验调查inotuzumab ozogamicin (InO) 在Ph-B细胞ALL的第一线治疗中.
分析这些试验的疗效和安全性数据.
专注于低强度化疗方案与向治疗相结合.

主要成果:

伊诺图祖马布奥佐加米辛 (InO) 在B细胞ALL中表现出强烈的活性.
在Ph-B细胞ALL中首线使用InO正在研究,以提高耐受性和疗效.
优化前线向治疗可能会减少对强化常规化疗的需要.

结论:

前线伊诺图祖马布 (ino) 为患有Ph-B细胞ALL的老年人提供了一种有前途的方法.
与传统化疗相比,有针对性的疗法可以潜在地提高治疗效率,同时降低毒性.
对优化B细胞向剂组合的进一步研究对于改善这一患者群体的治疗结果至关重要.

关键词:

化疗化疗是一种化学疗法.前线治疗前线治疗年龄较大的患者.费城染色体负的染色体有针对性的治疗.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.